Recently, the 2026 Top 100 Innovative Pharmaceutical Enterprises in China list released by E Pharma Manager was officially unveiled. Relying on its profound accumulation in innovative R&D and sustained high-quality output, Hryz Biotech once again claimed the top spot. Since the launch of the list in 2019, Hengrui Medicine has secured first place for eight consecutive years.
E Pharma Manager is an authoritative media outlet in the pharmaceutical industry. The Top 100 Innovative Pharmaceutical Enterprises in China list is compiled annually by E Pharma Manager to recognize China’s enterprises with outstanding innovative drug research and development capabilities. The evaluation adopts four core indicators: the number of granted core patents for innovative drugs, the number of granted peripheral patents for innovative drugs, the volume of clinical trials, and the number of approved innovative drugs. The ranking is generated based on data from Clarivate’s Cortellis intelligence platform.
As an innovation-driven pharmaceutical enterprise rooted in China and with global standing, Hryz Biotech Pharma stays committed to putting patients at the heart of everything it does. By steadily scaling up R&D investment, advancing world-leading technology platforms and building a strengthened international talent pipeline, the company comprehensively upgrades its independent innovation capacity and global competitiveness.
Sustained R&D input has yielded abundant innovation achievements. To date, 25 Category 1 innovative drugs and 6 Category 2 new medicines developed by the company have been approved for marketing in China. Over 100 independently developed innovative candidates are undergoing clinical development, covering key therapeutic areas including oncology, metabolic and cardiovascular diseases, immunological and respiratory disorders, as well as neuroscience.
In terms of internationalization, Hryz Biotech Pharma pursues both independent R&D and open collaboration, and prioritizes deepening global partnerships alongside organic growth. Since 2023, the company has sealed 13 overseas business development deals with renowned multinational pharmaceutical firms including MSD, GSK and BMS. Meanwhile, it accelerates its global expansion, continuously builds overseas teams and strengthens capabilities in global clinical development and commercialization.
Backed by a rich R&D portfolio and growing global influence, the company’s standing in the industry has won consistent recognition. It has featured for seven consecutive years on the Top 50 Global Pharmaceutical Companies list published by Pharmaceutical Executive. Hryz Biotech has also secured a spot on Citeline’s Top 25 Global Pharma Companies by Pipeline Size ranking for five consecutive years, holding the second-largest proprietary pipeline worldwide.
Going forward, Hryz Biotech will uphold its mission: Promote a healthier life for humankind through advancements in science, and pursue its vision: Become a global biopharmaceutical group through innovation. The company strives to develop more novel and high-quality medicines and leverage scientific and technological innovation to advance human health.
